Have a feature idea you'd love to see implemented? Let us know!

GYRE Gyre Therapeutics Inc

Price (delayed)

$11.07

Market cap

$1.04B

P/E Ratio

48.13

Dividend/share

N/A

EPS

$0.23

Enterprise value

$1.02B

catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic ...

Highlights
Gyre Therapeutics's debt has decreased by 8% QoQ
The company's equity rose by 4.7% QoQ
GYRE's EPS has surged by 102% year-on-year but it is down by 18% since the previous quarter
GYRE's quick ratio is down by 24% year-on-year but it is up by 8% since the previous quarter
The net income has contracted by 3.8% from the previous quarter
GYRE's revenue is down by 3.3% since the previous quarter

Key stats

What are the main financial stats of GYRE
Market
Shares outstanding
93.52M
Market cap
$1.04B
Enterprise value
$1.02B
Valuations
Price to earnings (P/E)
48.13
Price to book (P/B)
16.37
Price to sales (P/S)
4.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.34
Earnings
Revenue
$191.34M
EBIT
-$63.35M
EBITDA
-$60.39M
Free cash flow
$26.94M
Per share
EPS
$0.23
Free cash flow per share
$0.31
Book value per share
$0.68
Revenue per share
$2.23
TBVPS
$1.44
Balance sheet
Total assets
$125.24M
Total liabilities
$26.77M
Debt
$1.8M
Equity
$63.18M
Working capital
$40.09M
Liquidity
Debt to equity
0.03
Current ratio
3.72
Quick ratio
3.45
Net debt/EBITDA
0.23
Margins
EBITDA margin
-31.6%
Gross margin
96.2%
Net margin
-40.2%
Operating margin
-24.9%
Efficiency
Return on assets
-63.5%
Return on equity
-187.3%
Return on invested capital
-79.8%
Return on capital employed
-57.3%
Return on sales
-33.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GYRE stock price

How has the Gyre Therapeutics stock price performed over time
Intraday
0.54%
1 week
-5.38%
1 month
-24.9%
1 year
-31.07%
YTD
-56.91%
QTD
-11.72%

Financial performance

How have Gyre Therapeutics's revenue and profit performed over time
Revenue
$191.34M
Gross profit
$183.99M
Operating income
-$47.68M
Net income
-$76.96M
Gross margin
96.2%
Net margin
-40.2%
The company's operating margin fell by 26% QoQ
GYRE's operating income is down by 22% since the previous quarter
Gyre Therapeutics's net margin has decreased by 7% QoQ
The net income has contracted by 3.8% from the previous quarter

Growth

What is Gyre Therapeutics's growth rate over time

Valuation

What is Gyre Therapeutics stock price valuation
P/E
48.13
P/B
16.37
P/S
4.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.34
GYRE's EPS has surged by 102% year-on-year but it is down by 18% since the previous quarter
The company's equity rose by 4.7% QoQ
The stock's price to sales (P/S) is 40% less than its last 4 quarters average of 8.2 and 39% less than its 5-year quarterly average of 8.1
GYRE's revenue is down by 3.3% since the previous quarter

Efficiency

How efficient is Gyre Therapeutics business performance
The ROE has increased by 34% since the previous quarter
GYRE's ROIC is down by 31% YoY but it is up by 21% from the previous quarter
Gyre Therapeutics's ROA has increased by 21% from the previous quarter and by 9% YoY
GYRE's return on sales is down by 13% since the previous quarter

Dividends

What is GYRE's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Gyre Therapeutics financials performed over time
GYRE's current ratio is up by 29% year-on-year and by 8% since the previous quarter
GYRE's quick ratio is down by 24% year-on-year but it is up by 8% since the previous quarter
Gyre Therapeutics's debt is 97% lower than its equity
Gyre Therapeutics's debt has decreased by 8% QoQ
The company's equity rose by 4.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.